Breaking News Instant updates and real-time market news.

RTIX

RTI Surgical

$4.52 /

-0.265 (-5.54%)

, ALKS

Alkermes

$24.83 /

-0.46 (-1.82%)

08:08
05/20/19
05/20
08:08
05/20/19
08:08

UBS to hold a conference

Global Healthcare Conference will be held in New York on May 20-22 with webcasted company presentations to begin on May 20; not all company presentations may be webcasted. Webcast Link

RTIX

RTI Surgical

$4.52 /

-0.265 (-5.54%)

ALKS

Alkermes

$24.83 /

-0.46 (-1.82%)

HOLX

Hologic

$44.86 /

-0.21 (-0.47%)

ARNA

Arena Pharmaceuticals

$53.99 /

-1.8 (-3.23%)

HSIC

Henry Schein

$67.94 /

+0.85 (+1.27%)

VCYT

Veracyte

$24.39 /

-0.72 (-2.87%)

ESPR

Esperion

$51.77 /

+0.8 (+1.57%)

REGN

Regeneron

$304.81 /

-4.69 (-1.52%)

BRKS

Brooks Automation

$37.44 /

-0.51 (-1.34%)

HIIQ

Health Insurance Innovations

$23.80 /

+0.68 (+2.94%)

UHS

Universal Health

$121.95 /

+0.2 (+0.16%)

LMNX

Luminex

$21.01 /

-0.55 (-2.55%)

HRC

Hill-Rom

$97.36 /

-1.74 (-1.76%)

XLRN

Acceleron

$41.75 /

-0.2 (-0.48%)

MD

Mednax

$26.76 /

-0.455 (-1.67%)

ALXN

Alexion

$130.83 /

-0.63 (-0.48%)

BAX

Baxter

$75.97 /

-0.94 (-1.22%)

ABUS

Arbutus Biopharma

$2.40 /

-0.05 (-2.04%)

LHCG

LHC Group

$118.29 /

-0.43 (-0.36%)

ESTA

Establishment Labs

$26.80 /

+0.06 (+0.22%)

TTPH

Tetraphase

$0.84 /

-0.0034 (-0.41%)

BTAI

BioXcel Therapeutics

$10.72 /

-0.21 (-1.92%)

WAT

Waters

$208.17 /

-1.93 (-0.92%)

INCY

Incyte

$77.24 /

-0.43 (-0.55%)

TNDM

TNDM

/

+

CNCE

Concert Pharmaceuticals

$10.59 /

+0.01 (+0.09%)

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 24

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 13

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 17

    Jun

  • 26

    Jun

  • 28

    Jun

  • 05

    Aug

  • 13

    Nov

RTIX RTI Surgical
$4.52 /

-0.265 (-5.54%)

ALKS Alkermes
$24.83 /

-0.46 (-1.82%)

05/01/19
Fly Intel: Top five analyst downgrades
05/01/19 Citi
Citi downgrades Alkermes to Neutral on lack of upside catalysts
05/01/19 Citi
Alkermes downgraded to Neutral from Buy at Citi
04/25/19 Piper Sandler
Piper points to plateauing revenue as reason to stay Neutral on Alkermes
HOLX Hologic
$44.86 /

-0.21 (-0.47%)

04/24/19 Piper Sandler
Hologic checks suggest worsening Cynosure trends, says Piper Jaffray
01/31/19 Piper Sandler
Hologic price target raised to $49 from $45 at Piper Jaffray
01/04/19 Cowen
Hologic downgraded to Market Perform from Outperform at Cowen
01/02/19
Fly Intel: Top five analyst downgrades
ARNA Arena Pharmaceuticals
$53.99 /

-1.8 (-3.23%)

04/03/19 Credit Suisse
Arena Pharmaceuticals price target raised to $77 from $63 at Credit Suisse
01/29/19
Fly Intel: Top five analyst initiations
01/29/19 Cantor Fitzgerald
Arena Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald
12/13/18 Berenberg
Arena Pharmaceuticals initiated with a Buy at Berenberg
HSIC Henry Schein
$67.94 /

+0.85 (+1.27%)

05/15/19
Henry Schein downgraded to Market Perform on valuation at SVB Leerink
05/15/19 SVB Leerink
Henry Schein downgraded to Market Perform from Outperform at SVB Leerink
05/08/19 Barrington
Henry Schein price target raised to $75 from $72 at Barrington
05/08/19 Craig-Hallum
Henry Schein price target raised to $77 from $72 at Craig-Hallum
VCYT Veracyte
$24.39 /

-0.72 (-2.87%)

01/29/19 Lake Street
OncoCyte price target raised to $7 from $4 at Lake Street
01/04/19 BTIG
Veracyte price target raised to $17 from $15 at BTIG
10/31/18 Janney Montgomery Scott
Veracyte upgraded to Buy from Neutral at Janney Montgomery Scott
07/24/18 Piper Sandler
Veracyte price target raised to $11 from $7 at Piper Jaffray
ESPR Esperion
$51.77 /

+0.8 (+1.57%)

05/06/19 BofA
Esperion upgraded to Neutral from Underperform at BofA/Merrill
05/06/19 Jefferies
No plans for FDA panel removes Esperion bear case, says Jefferies
05/06/19 Credit Suisse
Esperion price target raised to $90 from $79 at Credit Suisse
05/02/19 Citi
Amarin selloff creates attractive entry point, says Citi
REGN Regeneron
$304.81 /

-4.69 (-1.52%)

05/20/19 Barclays
Barclays still bearish on Regeneron despite 18% drop year-to-date
05/16/19 JPMorgan
Regeneron selloff brings improved risk/reward, says JPMorgan
05/13/19 Cantor Fitzgerald
Regeneron price target lowered to $405 from $441 at Cantor Fitzgerald
05/08/19 BMO Capital
Regeneron price target lowered to $375 from $412 at BMO Capital
BRKS Brooks Automation
$37.44 /

-0.51 (-1.34%)

01/23/19 Citi
Citi moves Lam Research to top pick in Semiconductor Capital Equipment
12/17/18 Citi
Citi adds 'positive catalyst watch' on Brooks Automation
11/20/18 Credit Suisse
Brooks Automation price target lowered to $26 from $32 at Credit Suisse
09/04/18 B. Riley FBR
Brooks Automation price target raised to $50 from $40 at B. Riley FBR
HIIQ Health Insurance Innovations
$23.80 /

+0.68 (+2.94%)

05/08/19 Cantor Fitzgerald
Cantor views new Health Insurance disclosure on Simple Health positively
05/07/19 Lake Street
Health Insurance Innovations price target lowered to $50 from $80 at Lake Street
05/02/19 Raymond James
Health Insurance Innovations stock looks 'broken,' says Raymond James
03/29/19 Canaccord
New court filings read positive for Health Insurance Innovations, says Canaccord
UHS Universal Health
$121.95 /

+0.2 (+0.16%)

04/29/19 BMO Capital
Universal Health price target lowered to $138 from $146 at BMO Capital
04/17/19 Stephens
Issues facing healthcare sector now 'modest' compared to 2008-10, says Stephens
03/05/19 BMO Capital
Universal Health price target raised to $146 from $130 at BMO Capital
03/04/19
Fly Intel: Top five analyst downgrades
LMNX Luminex
$21.01 /

-0.55 (-2.55%)

09/27/18 Piper Sandler
Piper says about $3.5M of Luminex revenue at risk from Medicare determination
HRC Hill-Rom
$97.36 /

-1.74 (-1.76%)

11/27/18 UBS
Hill-Rom initiated with a Buy at UBS
10/15/18 Barclays
Hill-Rom initiated with an Equal Weight at Barclays
07/17/18 KeyBanc
Hill-Rom price target raised to $115 from $97 at KeyBanc
XLRN Acceleron
$41.75 /

-0.2 (-0.48%)

05/10/19 H.C. Wainwright
Acceleron price target raised to $69 from $66 at H.C. Wainwright
05/10/19 Piper Sandler
Acceleron price target raised to $74 from $71 at Piper Jaffray
05/03/19 Barclays
Acceleron downgraded to Equal Weight from Overweight at Barclays
04/22/19 Oppenheimer
Acceleron assumed with an Outperform from Perform at Oppenheimer
MD Mednax
$26.76 /

-0.455 (-1.67%)

04/11/19 Jefferies
Mednax price target lowered to $31 from $37 at Jefferies
01/17/19 Jefferies
Mednax assumed with a Hold at Jefferies
01/15/19 Citi
Citi upgrades Mednax to Buy with $44 target on 'discounted' valuation
01/14/19 Citi
Mednax upgraded to Buy from Neutral at Citi
ALXN Alexion
$130.83 /

-0.63 (-0.48%)

04/25/19 Piper Sandler
Piper remains buyer of Alexion shares to levels approaching $180
04/10/19 Raymond James
Alexion resumed with an Outperform at Raymond James
04/02/19 Piper Sandler
Piper says AAN meeting should be 'meaningful' for Alexion, Biogen
03/20/19 Piper Sandler
Alexion turnaround 'on full display' at investor meeting, says Piper Jaffray
BAX Baxter
$75.97 /

-0.94 (-1.22%)

05/13/19 JPMorgan
Baxter price target raised to $88 from $80 at JPMorgan
04/08/19
Baxter downgraded to In Line on valuation at Evercore ISI
04/08/19 Evercore ISI
Baxter downgraded to In Line from Outperform at Evercore ISI
04/03/19 Wells Fargo
Baxter price target raised to $89 from $80 at Wells Fargo
ABUS Arbutus Biopharma
$2.40 /

-0.05 (-2.04%)

10/16/18 B. Riley FBR
Arbutus Biopharma upgraded to Buy from Neutral at B. Riley FBR
10/15/18
Arbutus Biopharma upgraded to Neutral on valuation at Wedbush
10/15/18 Wedbush
Arbutus Biopharma upgraded to Neutral from Underperform at Wedbush
10/09/18 JMP Securities
Arbutus Biopharma downgraded earlier to Market Perform at JMP Securities
LHCG LHC Group
$118.29 /

-0.43 (-0.36%)

05/13/19 RBC Capital
LHC Group price target raised to $130 from $120 at RBC Capital
05/09/19 Jefferies
LHC Group price target raised to $130 from $125 at Jefferies
03/01/19 SunTrust
LHC Group price target raised to $130 from $115 at SunTrust
03/01/19 Craig-Hallum
LHC Group price target raised to $114 from $93 at Craig-Hallum
ESTA Establishment Labs
$26.80 /

+0.06 (+0.22%)

03/22/19 Canaccord
Breast implant panel documents in-line with expectations, says Canaccord
12/19/18 Jefferies
Establishment may benefit from Allergan breast implant issue, says Jefferies
11/14/18 BTIG
Establishment Labs price target raised to $40 from $35 at BTIG
08/14/18
On The Fly: Top five analyst initiations
TTPH Tetraphase
$0.84 /

-0.0034 (-0.41%)

05/10/19 SunTrust
Tetraphase price target lowered to $4 from $10 at SunTrust
03/16/19 Gabelli
Tetraphase downgraded to Hold from Buy at Gabelli
03/15/19 Piper Sandler
Tetraphase price target lowered to $4 from $6 at Piper Jaffray
01/04/19 B. Riley FBR
Tetraphase resumed with a Buy at B. Riley FBR
BTAI BioXcel Therapeutics
$10.72 /

-0.21 (-1.92%)

12/05/18 H.C. Wainwright
BioXcel Therapeutics data establish proof-of-concept, says H.C. Wainwright
WAT Waters
$208.17 /

-1.93 (-0.92%)

01/24/19 BTIG
Waters price target raised to $260 from $212 at BTIG
01/24/19 Baird
Baird downgrades Waters to Neutral, says organic growth looks priced in
01/24/19 Baird
Waters downgraded to Neutral from Outperform at Baird
01/03/19
Fly Intel: Top five analyst upgrades
INCY Incyte
$77.24 /

-0.43 (-0.55%)

05/15/19 Piper Sandler
Incyte price target raised to $95 from $85 at Piper Jaffray
05/03/19 Barclays
Incyte downgraded to Equal Weight from Overweight at Barclays
04/10/19 Stifel
Incyte initiated with a Hold at Stifel
04/09/19 JMP Securities
Concert Pharmaceuticals price target lowered to $20 from $26 at JMP Securities
TNDM TNDM
/

+

05/13/19 Piper Sandler
Tandem Diabetes' 'rapid' growth can continue, says Piper Jaffray
05/13/19 SVB Leerink
Tandem Diabetes initiated with an Outperform at SVB Leerink
05/01/19 Craig-Hallum
Tandem Diabetes price target raised to $84 from $70 at Craig-Hallum
05/01/19 Oppenheimer
Tandem Diabetes price target raised to $80 from $68 at Oppenheimer
CNCE Concert Pharmaceuticals
$10.59 /

+0.01 (+0.09%)

04/09/19 Stifel
Concert Pharmaceuticals price target lowered to $18 from $27 at Stifel
02/07/19 Mizuho
Concert Pharmaceuticals undervalued ahead of 2019 catalysts, says Mizuho
12/18/18 Mizuho
Concert remains best-in-class after Aclaris data, says Mizuho

TODAY'S FREE FLY STORIES

General news
Asian Market Update: » 01:50
02/27/20
02/27
01:50
02/27/20
01:50

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Syndicate
Freshpet 3.48M share Secondary priced at $66.00 » 23:43
02/26/20
02/26
23:43
02/26/20
23:43
FRPT

Freshpet

$67.36 /

-7.17 (-9.62%)

The deal priced below the…

The deal priced below the last closing price of $67.09. BofA is acting as lead book running manager for the offering.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27
    Feb
Upgrade
Wolters Kluwer upgraded to Neutral from Underweight at JPMorgan » 21:33
02/26/20
02/26
21:33
02/26/20
21:33
WTKWY

Wolters Kluwer

$0.00 /

+ (+0.00%)

JPMorgan analyst Daniel…

JPMorgan analyst Daniel Kerven upgraded Wolters Kluwer to Neutral from Underweight with a EUR 70 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
BioMarin firing on all cylinders, says Piper Sandler » 20:42
02/26/20
02/26
20:42
02/26/20
20:42
BMRN

BioMarin

$91.40 /

+0.37 (+0.41%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond keeps her Overweight rating and $120 price target on BioMarin after its Q4 earnings beat, saying the company's earnings call suggests that it is "firing on all cylinders". Given the implied meaningful growth projected for FY20 and the intermediate-stage pipeline updates on the horizon, the analyst expects the stock to break out of its 3-year rangebound pattern.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Global Blood Therapeutics Oxbryta results 'encouraging', says Piper Sandler » 20:36
02/26/20
02/26
20:36
02/26/20
20:36
GBT

Global Blood Therapeutics

$64.59 /

+0.11 (+0.17%)

Piper Sandler analyst…

Piper Sandler analyst Danielle Brill keeps her Overweight rating and $120 price target on Global Blood Therapeutics after its Q4 results. The analyst notes that the management's commentary suggests that Oxbryta launch is going well with $2.1M in contributed revenue, even though it was only available for a couple of weeks in December. Brill adds that she continues to view the demand for Oxbryta as high, and she is not concerned with the management holding off on providing hard launch metrics.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Innovative Industrial Properties reports Q4 EPS 78c, one estimate 57c » 20:31
02/26/20
02/26
20:31
02/26/20
20:31
IIPR

Innovative Industrial Properties

$96.08 /

-0.385 (-0.40%)

Reports Q4 revenue…

Reports Q4 revenue $17.7M, consensus $14.37M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Stepan Company updates on Millsdale Plant incident » 20:29
02/26/20
02/26
20:29
02/26/20
20:29
SCL

Stepan Company

$92.69 /

-0.82 (-0.88%)

On February 20, 2020, the…

On February 20, 2020, the fompany announced that its Millsdale plant was forced to stop production of Phthalic Anhydride and Surfactants due to power outage-related operational issues that impacted the site's waste water treatment plant. As a result, the company declared force majeure for the supply of PA and certain Surfactant product lines.

Earnings
Notable companies reporting before tomorrow's open » 20:25
02/26/20
02/26
20:25
02/26/20
20:25
BUD

AB InBev

$66.35 /

-0.5 (-0.75%)

, KDP

Keurig Dr Pepper

$28.72 /

-0.205 (-0.71%)

, BBY

Best Buy

$82.23 /

+0.365 (+0.45%)

, DISCA

Discovery

$26.50 /

-0.925 (-3.37%)

, NLSN

Nielsen

$20.29 /

-0.13 (-0.64%)

, SERV

ServiceMaster

$33.81 /

-2.515 (-6.92%)

, JCP

J.C. Penney

$0.73 /

+0.034 (+4.90%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include AB InBev (BUD), consensus $1.05... Keurig Dr Pepper (KDP), consensus 35c... Best Buy (BBY), consensus $2.75... Discovery (DISCA), consensus 93c... Nielsen (NLSN), consensus 42c... ServiceMaster (SERV), consensus 19c... J. C. Penney (JCP), consensus (6c).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
FreightCar America reports Q4 EPS (75c), two estimates (59c) » 20:07
02/26/20
02/26
20:07
02/26/20
20:07
RAIL

FreightCar America

$1.45 /

-0.07 (-4.61%)

Reports Q4 revenue…

Reports Q4 revenue $44.9M, one estimate $45.4M. Q4 backlog totaled 1,650 railcars with an aggregate value of approximately $206M. Jim Meyer, CEO of FreightCar America, says: "While industry conditions remained challenged, we focused on maintaining our internal momentum by executing against the last few steps of our 'Back to Basics' strategy. This included strong performance against our goals to remove over $5,000 per car in material costs over the last two years. It also included significant work to revamp our product portfolio to better align with customer needs. Lastly, we took important steps to optimize our manufacturing footprint through further domestic consolidation and a new partnership to expand into Mexico. The latter will allow us to increase the competitiveness of our portfolio. When complete, our footprint will include the industry's newest production facilities in both the U.S. and Mexico. As importantly, we completed this hard work while maintaining a solid and supportive balance sheet, despite the significant downcycle in our markets. All of our efforts in 2018 and 2019 have laid the framework for FreightCar to succeed in the next market cycle."

ShowHide Related Items >><<
Earnings
Cactus reports Q4 adj. EPS 38c, consensus 36c » 20:02
02/26/20
02/26
20:02
02/26/20
20:02
WHD

Cactus

$25.45 /

-0.8 (-3.05%)

Reports Q4 revenue…

Reports Q4 revenue $140.2M, consensus $141.69M. Reports Q4 adj. EBITDA $48.4M vs. $58.8M last year. CEO Scott Bender says: "2019 was a record year for Cactus. Despite a larger than anticipated decline in the overall U.S. onshore rig count during the fourth quarter, our results were generally consistent with our expectations. The overall margin profile of the business remained strong, notwithstanding the typical seasonal slowdown in Field Service due in part to lower completions activity driven by E&P budget exhaustion. The quarter highlighted the Company's ability to generate significant free cash flow, with cash growing by over $35 million during the period, net of nearly $7 million in dividend payments and associated distributions. Looking to the first quarter of 2020, customers have again shown a willingness to quickly increase completion activity following the reset of budgets in January. We currently anticipate that revenue across all our business lines will increase relative to the fourth quarter of 2019. Additionally, the adoption of our new frac innovations has continued to progress during the first quarter. During our time as a public entity, Cactus has demonstrated its ability to perform well in the face of a challenging market environment. Going forward, we believe the capital-light nature of the business will further separate us from our peers, and we expect 2020 to highlight our ability to gain market share at attractive margins and generate substantial free cash flow."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
SJW Group sees FY20 EPS $2.25-$2.35, consensus $2.31  19:59
02/26/20
02/26
19:59
02/26/20
19:59
SJW

SJW Group

$69.38 /

+0.24 (+0.35%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
SJW Group reports Q4 EPS 34c ex expenses, consensus 41c » 19:58
02/26/20
02/26
19:58
02/26/20
19:58
SJW

SJW Group

$69.38 /

+0.24 (+0.35%)

Reports Q4 revenue…

Reports Q4 revenue $125.8M, consensus $121.28M. SJW Group President & CEO Eric Thornburg stated "Our transformative merger with CTWS positions us for future growth and success. We are incredibly proud of this achievement. We are also very pleased to begin to move forward with a focus on realizing the combination's benefits for all of our stakeholders."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
SPDR Gold Shares holdings fall to 935.70MT from 940.09MT » 19:53
02/26/20
02/26
19:53
02/26/20
19:53
GLD

SPDR Gold Shares

$153.95 /

+0.62 (+0.40%)

This is the first decline…

This is the first decline in holdings since January 31st.

General news
CDC reports first U.S. coronavirus case of unknown origin, Bloomberg reports » 19:50
02/26/20
02/26
19:50
02/26/20
19:50
SPY

SPDR S&P 500 ETF Trust

$311.66 /

-1.04 (-0.33%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

Says the case has no ties…

Says the case has no ties to a known outbreak.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Forterra sees FY20 adj. EBITDA $210M-$240M vs. $203.9M in FY19 » 19:47
02/26/20
02/26
19:47
02/26/20
19:47
FRTA

Forterra

$14.24 /

-0.37 (-2.53%)

Sees FY20 capex…

Sees FY20 capex $45M-$55M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Forterra reports Q4 EPS (12c), consensus (13c) » 19:45
02/26/20
02/26
19:45
02/26/20
19:45
FRTA

Forterra

$14.24 /

-0.37 (-2.53%)

Reports Q4 revenue…

Reports Q4 revenue $363.1M, consensus $346.91M. Reports Q4 adj. EBITDA $41.5M vs. $32.9M last year. Forterra CEO Karl Watson, Jr. commented, "Our fourth quarter results reflect another step forward in our journey to earning a full and fair return on the products we produce and the capital we have deployed. We had a solid finish to the year with increased volume in both of our businesses largely due to favorable weather, continued pricing improvements, and reduced scrap costs in our Water segment. These benefits were partially offset by higher operating expenses reflecting our investments in manufacturing activities to improve future operational efficiencies. As a result, we exceeded our annual earnings and debt reduction targets for the year."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Mack-Cali Realty sees FY20 core FFO $1.24-$1.36, consensus $1.45  19:43
02/26/20
02/26
19:43
02/26/20
19:43
CLI

Mack-Cali Realty

$20.05 /

-0.4 (-1.96%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Mack-Cali Realty reports Q4 FFO 44c, consensus 41c » 19:42
02/26/20
02/26
19:42
02/26/20
19:42
CLI

Mack-Cali Realty

$20.05 /

-0.4 (-1.96%)

Reports Q4 revenue…

Reports Q4 revenue $86.7M, consensus $136.76M. Reports Q4 same-store NOI up 3.5%. Michael DeMarco, CEO, stated, "In 2019, we achieved a number of important milestones, including the completion of over $2.1 billion of transactions and the launch of our final non-core disposition initiative. Waterfront office leasing, while slower than prior years, is beginning to show some improvement; and our residential properties continue to perform ahead of our expectations. Leasing and balance sheet management are top priorities in 2020 as we continue to work to maximize value for our shareholders."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
NiSource sells Columbia Gas of Massachusetts to Eversource » 19:36
02/26/20
02/26
19:36
02/26/20
19:36
NI

NiSource

$27.79 /

-0.6 (-2.11%)

, ES

Eversource

$93.45 /

-0.05 (-0.05%)

NiSource (NI) announced…

NiSource (NI) announced that it has entered into a definitive agreement under which Eversource Energy (ES) will acquire Columbia Gas of Massachusetts' business. With Columbia Gas, Eversource will serve 626,000 natural gas customers in Massachusetts alone across more than 60 communities. Until the close of the transaction, which is expected to occur by the end of the third quarter 2020, NiSource will continue to remain focused on driving customer safety and service at Columbia Gas, as well as continuing to make ongoing enhancements in all areas of operations going forward.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
FDA advisory committee votes in favor of Eli Lilly's ramucirumab in NSCLC » 19:32
02/26/20
02/26
19:32
02/26/20
19:32
LLY

Eli Lilly

$133.47 /

-1.9 (-1.40%)

Eli Lilly announced that…

Eli Lilly announced that a FDA Oncologic Drugs Advisory Committee voted 6-5 that CYRAMZA, or ramucirumab, plus erlotinib demonstrated a favorable benefit/risk profile for patients with untreated metastatic EGFR-positive non-small cell lung cancer, or NSCLC, based on the results of the positive Phase 3 RELAY study. The ODAC considered the safety and efficacy data from the Phase 3 RELAY trial, which is the basis for the CYRAMZA supplemental Biologics License Application currently under review by the FDA. In the RELAY study, CYRAMZA, a VEGF receptor 2 antagonist, in combination with erlotinib, a globally approved EGFR-targeting tyrosine kinase inhibitor, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival - the time patients live without their disease getting worse - compared to erlotinib alone. "Given the unmet need that remains in treating metastatic EGFR-mutated non-small cell lung cancer, we are encouraged that the majority of these experts agree CYRAMZA plus erlotinib has a favorable benefit/risk profile for the first-line treatment of these patients," said Maura Dickler, M.D., vice president of late phase development, Lilly Oncology. "We believe in the clinical meaningfulness of the data from the RELAY trial, which targeted the VEGFR and EGFR pathways together. We look forward to continuing to work with the FDA on this application to offer a new front-line treatment option for people with metastatic EGFR-mutated non-small cell lung cancer.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Grupo Simec reports Q4 net loss MXN2.63B vs. profit MXN330M last year » 19:28
02/26/20
02/26
19:28
02/26/20
19:28
SIM

Grupo Simec

$9.85 /

+ (+0.00%)

Reports Q4 revenue…

Reports Q4 revenue MXN7.32B vs. MXN8.88B last year.

General News
Trump says he thinks stock market will recover  19:08
02/26/20
02/26
19:08
02/26/20
19:08
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$311.66 /

-1.04 (-0.33%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Insight Enterprises announces $50M stock buyback » 19:07
02/26/20
02/26
19:07
02/26/20
19:07
NSIT

Insight Enterprises

$55.21 /

-0.46 (-0.83%)

Insight Enterprises…

Insight Enterprises announced that its board of directors has authorized the repurchase of up to $50M of the company's common stock. The company's share repurchases will be made on the open market, through block trades, through 10b5-1 plans or otherwise. The number of shares purchased, and the timing of the purchases will be based on working capital requirements, general business conditions and other factors. The company intends to retire the repurchased shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General News
Trump says 'not the right time' for more South Korea, Italy travel restrictions  19:06
02/26/20
02/26
19:06
02/26/20
19:06
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$311.66 /

-1.04 (-0.33%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: After Hours Movers » 19:03
02/26/20
02/26
19:03
02/26/20
19:03
SPT

Sprout Social

$17.70 /

-1.11 (-5.90%)

, TDOC

Teladoc

$116.89 /

-1.55 (-1.31%)

, AKRX

Akorn

$1.29 /

-0.04 (-3.02%)

, ALIM

Alimera Sciences

$6.38 /

-0.06 (-0.93%)

, ETSY

Etsy

$50.64 /

+0.73 (+1.46%)

, ESTC

Elastic

$63.78 /

-2.235 (-3.39%)

, DDD

3D Systems

$10.24 /

-0.355 (-3.35%)

, BOX

Box

$14.98 /

-0.075 (-0.50%)

, NTRA

Natera

$34.76 /

-0.2 (-0.57%)

, CPE

Callon Petroleum

$2.21 /

-0.14 (-5.96%)

, UPWK

Upwork

$8.13 /

-0.19 (-2.28%)

, SQ

Square

$76.63 /

-0.38 (-0.49%)

, CLW

Clearwater Paper

$26.98 /

+0.71 (+2.70%)

, RUBI

Rubicon Project

$11.03 /

-0.6 (-5.16%)

, NDLS

Noodles & Company

$7.90 /

-0.35 (-4.24%)

, OPK

Opko Health

$1.39 /

-0.005 (-0.36%)

, ARNA

Arena Pharmaceuticals

$46.98 /

-0.93 (-1.94%)

, ACAD

Acadia

$40.30 /

-0.37 (-0.91%)

, SWX

Southwest Gas

$71.84 /

-2.02 (-2.73%)

, CLGX

CoreLogic

$48.39 /

+ (+0.00%)

, QGEN

Qiagen

$35.08 /

+0.09 (+0.26%)

, GILD

Gilead

$74.70 /

+4.57 (+6.52%)

, CLR

Continental Resources

$20.79 /

-1.125 (-5.13%)

, NTNX

Nutanix

$32.65 /

-2.08 (-5.99%)

, TPC

Tutor Perini

$11.99 /

+0.46 (+3.99%)

, QEP

QEP Resources

$2.16 /

-0.105 (-4.64%)

, MED

Medifast

$94.05 /

-1.09 (-1.15%)

, CVNA

Carvana

$101.66 /

-2.535 (-2.43%)

, LHCG

LHC Group

$150.40 /

+1.81 (+1.22%)

, FRGI

Fiesta Restaurant

$9.07 /

-0.91 (-9.12%)

, CCI

Crown Castle

$162.74 /

-0.33 (-0.20%)

, PTLA

Portola Pharmaceuticals

$12.51 /

-0.13 (-1.03%)

, PDCE

PDC Energy

$18.48 /

-1 (-5.13%)

, ANSS

Ansys

$273.00 /

+6.64 (+2.49%)

, SILK

Silk Road Medical

$45.25 /

-1.29 (-2.77%)

, RGNX

Regenxbio

$47.50 /

+0.13 (+0.27%)

, LB

L Brands

$22.77 /

-0.76 (-3.23%)

, NTES

NetEase

$345.55 /

+7.47 (+2.21%)

, BKNG

Booking Holdings

$1,683.38 /

-44.63 (-2.58%)

, MSFT

Microsoft

$170.20 /

+2.14 (+1.27%)

UP AFTER EARNINGS: Sprout…

UP AFTER EARNINGS: Sprout Social (SPT) up 18.6%... Teladoc (TDOC) up 17.2%... Akorn (AKRX) down 12.7%... Alimera Sciences (ALIM) up 11.5%... Etsy (ETSY) up 10.6%... Elastic (ESTC) up 10.5%... 3D Systems (DDD) up 9.2%... Box Inc (BOX) up 8.8%... Natera (NTRA) up 8.7%... Callon Petroleum (CPE) up 8.1%... Upwork (UPWK) up 8.0%... Square (SQ) up 7.4%... Clearwater Paper (CLW) up 5.6%... Rubicon Project (RUBI) up 5.5%... Noodles & Co (NDLS) up 5.4%... Opko Health (OPK) up 5.1%... Arena Pharma (ARNA) up 4.5%... Acadia Pharma (ACAD) up 4.1%... Southwest Gas (SWX) up 4.0%... Corelogic (CLGX) up 2.1%. ALSO HIGHER: Qiagen (QGEN) up 3.3% after announcing shipments of coronavirus test kits... Gilead (GILD) up 3.0% after initiating two phase 3 studies of antiviral Remdesivir in coronavirus. DOWN AFTER EARNINGS: Continental Resources (CLR) down 17.0%... Nutanix (NTNX) down 16.0%... Tutor Perini (TPC) down 15.8%... QEP Resources (QEP) down 14.8%... Medifast (MED) down 14.3%... Carvana (CVNA) down 10.7%... LHC Group (LHCG) down 6.9%... Fiesta Restaurant (FRGI) down 6.6%... Crown Castle (CCI) down 5.7%... Portola Pharma (PTLA) down 5.2%... PDC Energy (PDCE) down 5.0%... Ansys (ANSS) down 3.8%... Silk Road Medical (SILK) down 2.5%... Regenexbio (RGNX) down 2.3%... L Brands (LB) down 2.1%... NetEase (NTES) down 1.7%... Booking Holdings (BKNG) down 0.5%. ALSO LOWER: Microsoft (MSFT) down 1.4% after saying will not meet Q3 guidance in More Personal Computing segment. Movers as of 18:30ET.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.